3D cell cancer systems for disease modeling, patient drug response prediction and personalized medicine

ZetaBio is a research-driven initiative dedicated to the treatment of cancer by adopting next-generation human-relevant 3D organoids and organ-on-chip systems for disease modeling, drug screening, and personalized medicine applications.

Amid rising global cancer incidence and persistently high clinical failure rates, ZetaBio seeks to deliver a transformative solution to accelerate the development of safer, more effective therapies.

New cases of Breast Cancer in 2022
0
Worldwide Deaths in 2022
0
Lifetime risk (1 in 8 women)
0 %
of drugs fail clinical trials
0 %
Our vision

Shaping the Future of 3D-Based Therapeutics against Cancer

ZetaBio envisions a collaborative research ecosystem where scientists connect, co-author impactful publications, and evolve into strategic partners in competitive funding proposals.

By fostering structured subgroups and scaling toward institutional alliances, we aim to bridge ideas and infrastructure, ultimately paving the way for a sustainable, research-driven enterprise with purpose, integrity, and translational impact at its core.

ZetaBio group

Core focus areas

01.

Drug Development & Screening

Design and optimization of advanced drug formulations, delivery systems, and preparation methods.

02.

2D Cell Culture Models

Use of breast cancer cell lines in monolayer cultures for preliminary testing of drug efficacy and cytotoxicity.

03.

3D Cell Culture Systems

Development of 3D breast cancer models that better replicate tumor architecture and microenvironment.

04.

Spheroids & Organoids

Engineering and use of complex multicellular models to study tissue-specific responses to compounds.

05.

Advanced Drug Screening Platforms

Integration of breast cancer-specific cell models with high-content screening tools for evaluating therapeutic efficacy.

06.

Integrated In Vitro Approaches

Combining 2D, 3D, and organoid systems to create robust preclinical models for breast cancer drug development.

Open Collaboration

Ethical Research

Interdisciplinary Thinking

Accessible Science

Covid-19 Contagion

What our group values?

We believe science thrives through open communication, cross-discipline input, and ethical responsibility.

Zeta Bio news

Latest news, events & more

Nec habitasse sociis urna urna dignissim et ac parturient sed mi ultricies porttitor ligula eu elementum arcu leo, cum tellus suspendisse dignissim habitant pellentesque.

ZetaBio at Researcher's Night 2026

ZetaBio Group is participating at Researchers’ Night 2026 on Friday, September 25, 2026, at the Conference and Cultural Center of the University of Patras, Greece.

New Collaboration on 3D culture facilities

ZetaBio strengthens its research infrastructure by accessing specialized laboratories in UK, supporting advanced 3D cell culture development.

New publications from ZetaBio

Our latest publications

ZetaBio Attends 2025 BioStart Competition

We’re proud to announce our participation in the BioSTART Competition at the Bio3 Forum in Athens, Greece, September 15-19, 2025.

Zeta Bio news

Our members affiliations

Nec habitasse sociis urna urna dignissim et ac parturient sed mi ultricies porttitor ligula eu elementum arcu leo, cum tellus suspendisse dignissim habitant pellentesque.